SAN FRANCISCO (Thomson Financial) - Bayer AG's Bayer HealthCare Pharmaceuticals Inc. plans to remove the remaining stock of its clotting drug Trasylol from the U.S. market, the Food and Drug Administration said Wednesday.
Most of the drug, which is used to control bleeding during heart surgery, is in warehouses and hospital or physician's stock, the agency said. Access to the medication has been limited to investigational use.
In November 2007, Bayer (nyse: BAY - news - people ) agreed to an FDA-requested marketing suspension of Trasylol. At that time, preliminary results from a Canadian study suggested an increased risk for death compared to two other drugs used to control bleeding, the FDA said.